novo nordisk fda semaglutide approves higher-dose Wegovy to help people lose more weight Novo Nordisk just played one

They want compounds that preserve muscle during weight loss

This can be uncomfortable and may require dietary changes or medical intervention

Patient education about expected side effects, their typical time course, and management strategies significantly improves treatment adherence and outcomes

Over 12 weeks, it can be as high as 10%

This means the generic delivers the same amount of active ingredient into the bloodstream in the same amount of time

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for type 2 diabetes that was subsequently found to produce substantial weight loss